Researchers have developed and tested a synthetic atherosclerosis drug that can reduce the build-up of dangerous blood vessel plaques without producing the side-effect of fatty liver disease (which leads to its own set of problems like diabetes). The encouraging results of this study in mice could lead to a new type of drug to treat or even prevent atherosclerosis.
Targets of this drug, called DMHCA, are proteins called the Liver X Receptors (LXR). These proteins control a body's cholesterol levels by limiting the absorption of dietary cholesterol and by increasing the conversion of cholesterol into bile acids. Unfortunately, most LXR ligands also control fatty acid production, so therapeutic compounds that activate LXR also raise the levels of other fats, particularly in the liver.
DHMCA, though, had negligible effects of fat production in laboratory tests, so Dagmar Kratky and colleagues tested it in mice genetically engineered to be atherosclerotic. They found that compared to another experimental LXR drug (T0901317), DMHCA could significantly reduce the size of arterial lesions in the mice (45-48%) without increasing fat content in the liver or blood.
Together, these results, appearing in the February Journal of Lipid Research, show much therapeutic promise.
The above story is based on materials provided by American Society for Biochemistry and Molecular Biology. Note: Materials may be edited for content and length.
- Kratzer et al. Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia. The Journal of Lipid Research, 2008; 50 (2): 312 DOI: 10.1194/jlr.M800376-JLR200
Cite This Page: